BROOKSBrooks Laboratories Ltd.

₹123.85-0.77%

Market Cap

₹368.66 Cr

Stock P/E

-903.61

ROCE

-24.92%

ROE

-28.08%

Book Value

₹34.20

Financials

YoY Net Sales

EPS Growth

Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings

Distribution

Promoter

Institution

Public

Others

From Last Concall

No Concall Summary

Conference call summary is not available for this stock.

Peers Summary

Sector Leader

Brooks Laboratories Ltd. is underperforming its peers in terms of profitability and valuation metrics, primarily due to negative earnings and high PE ratio. However, it shows impressive revenue growth, suggesting potential for recovery. In contrast, companies like Cipla Ltd. and Dr. Reddy's Laboratories Ltd. are strong performers with solid profitability and reasonable valuation, making them attractive for investors.

Key Points

• Brooks Laboratories shows high revenue growth (25.76% YoY), but has negative EPS and ROE.
• Cipla Ltd. and Dr. Reddy's Laboratories Ltd. lead in profitability with strong EPS and ROE.
• Divi's Laboratories is the most overvalued based on PE ratio (73.20) despite decent margins.
• Sun Pharmaceutical and Mankind Pharma show good growth and reasonable valuations.

Top Performers

Cipla Ltd.

Strong profitability metrics with a low PE ratio, making it attractive for investors.

Dr. Reddy's Laboratories Ltd.

Excellent ROE and strong growth in EPS, indicating solid financial health.

Mankind Pharma Ltd.

High revenue growth and strong margins, suggesting effective operational management.